5 Amino 1mq
$135.00 – $195.00
Bestseller Research Information
Overview
Retatrutide is an investigational triple GIP/GLP-1/glucagon receptor agonist. As of October 2026, Lilly has reported positive Phase 3 topline results; it remains investigational and is not approved for individual use.
Analytical Documentation
Each lot carries an independently performed HPLC purity assessment and an ESI-MS identity check, keyed to its batch number and available online. Purity and identity results are lot-specific; read them against the corresponding batch record rather than assuming one result applies to every batch. Refer to the batch record lookup for the file matching this vial.
References
For primary research, refer to peer-reviewed literature indexed in PubMed and trial records on ClinicalTrials.gov. These sources are provided for scientific reference and are not an endorsement of this product or any use of it:
Research and Regulatory Limitations
This page provides reference information for laboratory research. It does not provide medical advice, dosing instructions, or guidance for human use. Research-use labeling does not, by itself, establish that a product or its sale is lawful in a particular jurisdiction. See the disclaimer and research-use statement.
